Table 6: **Tat**

МАЬ П	Location	WEAU	Sequence	Neutralizing	Immunogen	Species(Isotype)
200 1.2	Tat(1-16) Donor: ?	Tat(2-17)	EPVDPRLEWKHPGSQ?			
	References: [Ovod et al.(1992), Ranki et al.(1995)] NOTES: • 1.2: Weak expression of Tat observed in HIV+	992), Ranki et al.(1 of Tat observed in F	 eferences: [Ovod et al.(1992), Ranki et al.(1995)] OTES: 1.2: Weak expression of Tat observed in HIV+ brain tissue sample, in contrast to Nel 	ontrast to Nef [Ran	f [Ranki et al.(1995)]	
201 1D9D5	Tat(1-20 N-term)	Tat(2-21)	EPVDPRLEWKHPGSQPK. TA	1	rec HIV-1 tat A	$\operatorname{murine}(\operatorname{IgG}_1)$
	Donor: ? References: [Mhashilkar et al.(1995), Valvatne et al.(1996)] NOTES:	et al.(1995), Valvatn	e et al.(1996)]			
	 1D9D5: Single chain antibodies ("intrabodies") were mammalian cells – co-expression of an N-term "intral and block import into nucleus, but "intrabody" species 1D9D5: Exogenously delivered Tat can efficiently presence of 1D9D5, suggesting when considered with Ab bound is taken up by cells [Valvatne et al.(1996)] 	antibodies ("intrabe expression of an N- nucleus, but "intrab delivered Tat can o aggesting when con by cells [Valvatne et	1D9D5: Single chain antibodies ("intrabodies") were engineered that can be stably expressed in the cytoplasm of mammalian cells – co-expression of an N-term "intrabody" can inhibit transactivation of an HIV LTR-CAT construct and block import into nucleus, but "intrabody" specific for exon 2 did not inhibit activity [Mhashilkar et al.(1995)] 1D9D5: Exogenously delivered Tat can efficiently transactivate an HIV-LTR-CAT construct in HeLa cells in the presence of 1D9D5, suggesting when considered with the results of [Mhashilkar et al.(1995)], that free Tat and not Ab bound is taken up by cells [Valvatne et al.(1996)]	an be stably exprinsactivation of ar inhibit activity V-LTR-CAT constantillar et al.(19)	expressed in the cytoplasm of of an HIV LTR-CAT construct vity [Mhashilkar et al.(1995)] construct in HeLa cells in the ul.(1995)], that free Tat and not	
202 NT3/2D1.1	Tat(2-15 N-term) Donor: ? References: [Dingwall et al.(1989)] NOTES: NT3/2D1.1: Immunoprecipitate NT3/2D1.1: UK Medical Resea	Tat(2-15) al.(1989)] recipitates and imm cal Research Counc	2-15 N-term) Tat(2-15) EPVDPNLEPWNHPS P tor: ? rerences: [Dingwall et al.(1989)] IES: NT3/2D1.1: Immunoprecipitates and immunoblots HIV-1 tat protein [Dingwall et al.(1989)] NT3/2D1.1: UK Medical Research Council AIDS reagent: ARP352	ingwall et al.(198	Peptide tat(2-15) 9)]	$murine(IgG_1a)$
203 ID2F11	Tat(49-86 C-term)	Tat(?49-86)	RKKRRQRRRPPQGSQT- HQVSLSKQPTSQSRGDP- TGPKE		full length purified rec tat A	$\operatorname{murine}(\operatorname{IgG}_1)$
	Donor: ? References: [Valvatne et al.(1996)] NOTES: • 1D2F11: MAb did not bind sh HIV-LTR-CAT construct in Hel	I.(1996)] t bind shorter pepti ct in HeLa cells by	or: ? erences: [Valvatne et al.(1996)] TES: 1D2F11: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by inhibition of cellular uptake of Tat [Valvatne et al.(1996)]	genously delivered f Tat [Valvatne et	Tat transactivation of an al.(1996)]	-

MAb ID	Location	WEAU	Sequence	Neutralizing	Immunogen	Species(Isotype)
204 4B4C4	Tat(49-86 C-term)	Tat(?49-86)	RKKRRQRRRPPQGSQT- HQVSLSKQPTSQSRGDP- TGPKE		full length purified rec tat A	$\mathrm{murine}(\mathrm{IgG}_1)$
	Donor: ? References: [Valvatne et al.(1996), Jensen et al.(1997)] NOTES: • 4B4C4: Also called 4B4 • 4B4C4: MAb did not bind shorter peptides – this HIV-LTR-CAT construct in HeLa cells by inhibitio	996), Jensen et a d shorter peptid n HeLa cells by	or: ? erences: [Valvatne et al.(1996), Jensen et al.(1997)] TES: 4B4C4: Also called 4B4 4B4C4: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by inhibition of cellular uptake of Tat [Valvatne et al.(1996)]	nously delivereo Tat [Valvatne et	l Tat transactivation of al.(1996)]	an
205 2D9E7	Tat(49-86 C-term)	Tat(?49-86)	RKKRRQRRRPPQGSQT- HQVSLSKQPTSQSRGDP- TGPKE		full length purified rec tat A	$murine(IgG_1)$
	Donor: ? References: [Valvatne et al.(1996)] NOTES:	996)]				
	 2D9E7: MAb did not bind short HIV-LTR-CAT construct in HeLz or 4B4C4 [Valvatne et al.(1996)] 	id shorter peptid n HeLa cells by i (1996)]	2D9E7: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by inhibition of cellular uptake of Tat, but less efficiently than MAbs 1D2F11 or 4B4C4 [Valvatne et al.(1996)]	nously delivered at, but less effic	Tat transactivation of iently than MAbs 1D2F	an '11
206 5G7D8	Tat(49-86 C-term)	Tat(?49-86)	RKKRRQRRRPPQGSQT- HQVSLSKQPTSQSRGDP- TGPKE		full length purified rec tat A	$murine(\mathrm{Ig}\mathrm{G}_1)$
	Donor: ? References: [Valvatne et al.(1996)] NOTES:	996)]				
	• 5G7D8: MAb did not bind sh HIV-LTR-CAT construct in H 4B4C4 [Valvatne et al.(1996)]	nd shorter peptid in HeLa cells by	5G7D8: MAb did not bind shorter peptides – this MAb inhibited exogenously delivered Tat transactivation of an HIV-LTR-CAT construct in HeLa cells by inhibition of cellular uptake of Tat, but less efficiently than 1D2F11 or 4B4C4 [Valvatne et al.(1996)]	nously delivered f Tat, but less e	ivered Tat transactivation of an less efficiently than 1D2F11 or	an or
207 NT2/- 4D5.24	Tat(C-term 73-86)	Tat(73-86)	PTSQPRGDPTGPKE		Peptide Tat(73-86)	murine
	Donor: ? References: [Dingwall et al.(1989)] NOTES: • NT2/4D5.24: Immunoprecipita	989)] cipitates and imr	 onor: ? eferences: [Dingwall et al.(1989)] OTES: NT2/4D5.24: Immunoprecipitates and immunoblots HIV-1 tat protein [Dingwall et al.(1989)] 	ingwall et al.(19	89)]	

HIV Monoclonal Antibodies

MAb ID	Location	WEAU Sequence	Neutralizing	Immunogen
208 2D9D5	Tat(C-term)	Tat		purified, recombinant HIV-1 Tat
	Donor: ?			
	References: [Mhashilkar et al.(1995)] NOTES:	ar et al.(1995)]		
	• 2D9D5: Single chi mammalian cells – in contrast to MAb	in antihadiaa ("intrahadiaa") wara angii	naarad that can be stably ever	
209 L-anti-Tat	Tat	mammalian cells – co-expression of C-term "intrabody" did not inhibit transactivation in contrast to MAb 1D9D5 [Mhashilkar et al.(1995)]	not inhibit transactivation of an	expressed in the cytoplasm of n of an HIV LTR-CAT construct,
	Donor: AGMED, Inc., Bedford, MA USA References: [Cruikshank et al.(1997)] NOTES:	co-expression of C-term "intrabody" did I 1D9D5 [Mhashilkar et al.(1995)] Tat Bedford, MA USA nk et al.(1997)]	not inhibit transactivation of an HIV LTR LP (when lipidated) rec Tat	ssed in the cytoplasm of the HIV LTR-CAT construction of the transfer of the t